Four options manage localized RCC — active surveillance, thermal ablation, partial nephrectomy, and radical nephrectomy — and the choice balances oncologic control against renal-function preservation, since many patients have baseline CKD. Locally advanced disease (venous tumour thrombus, T4) is managed surgically, and adjuvant pembrolizumab now has a role in high-risk resected clear-cell disease. See the Radical Nephrectomy and Robotic Partial Nephrectomy procedure pages for operative technique.
Treatment Options
For a small renal mass, partial nephrectomy is preferred for any cT1 mass when feasible; thermal ablation and active surveillance suit smaller masses in older/comorbid patients, and radical nephrectomy is reserved for high-complexity tumours. Counsel on CKD risk — predictors of post-operative CKD include older age, diabetes, hypertension, male sex, obesity, smoking, a larger tumour, and post-operative AKI.
Active Surveillance
Small renal masses grow slowly (median 0.12–0.34 cm/yr) with a low metastasis rate (1–2% over 2–4 years). It is the preferred strategy for masses <2 cm and an option for 2–4 cm, especially with advanced age, life expectancy <5 years, significant comorbidity, or CKD ≥3b. Triggers for intervention: size >3–4 cm, growth >5 mm/yr (AUA) or >0.5 cm/yr (CUA), stage progression, unfavourable biopsy, or patient choice. Surveillance imaging runs every 3–6 months initially, with annual chest imaging.
Thermal Ablation
Radiofrequency ablation and cryoablation are options for cT1a solid masses <3 cm (best <2.5–3 cm; unreliable >4 cm) in older/comorbid patients or hereditary multifocal disease. They have low morbidity and comparable cancer-specific survival to PN in selected patients, but a higher local recurrence (cryo 3–10%, RFA 5–20%) than PN (0–3%) or RN (0%) — recurrences are usually salvageable with repeat ablation. Biopsy before or at the time of ablation. On follow-up, a successfully ablated tumour shows no contrast enhancement (RFA lesions don't shrink); residual enhancement signals recurrence — so ultrasound is not used for post-ablation surveillance.
Partial vs Radical Nephrectomy
Partial nephrectomy preserves renal function (median ~10% GFR loss vs ~35–40% for RN) at the cost of higher transfusion and urologic complications (urine leak) and a risk of hyperfiltration injury (proteinuria first; treat with an ACE inhibitor and low-protein diet). The number of preserved nephrons is the primary determinant of post-operative function; keep warm ischaemia <25 minutes (or use hypothermia). A negative margin is the goal — margin width does not matter, and a positive margin warrants close surveillance rather than re-excision.
| Approach | Preferred for |
|---|---|
| Partial nephrectomy | Any cT1a (and feasible cT1b); absolute — solitary kidney, bilateral tumours, familial RCC; relative — CKD, proteinuria, young age, multifocal disease |
| Radical nephrectomy | High-complexity tumour with no CKD/proteinuria and a normal contralateral kidney (expected eGFR >45); standard for cT2 and most cT3 |
The randomized EORTC 30904 found RN gave better overall survival than PN (a much-criticised result, extinguished in the RCC-histology subgroup), with no cancer-specific difference and better renal function with PN — so PN is preferred for T1a (<4 cm), while T1b/T2 with a normal contralateral kidney is debatable.
Lymphadenectomy and Adrenalectomy
- Lymphadenectomy — landing zones are interaortocaval (right) and para-aortic (left). EORTC 30881 showed no survival benefit in cN0 disease (only 4% pN+), so it is not routine for cN0; it is recommended for cN+ (staging/prognosis) and considered with high-risk features (size >10 cm, grade 3–4, sarcomatoid, necrosis, extrarenal extension, thrombus).
- Adrenalectomy — preserve the ipsilateral adrenal unless imaging or exploration suggests involvement (adrenal metastasis <5%; CT has a 99.4% negative predictive value); removing an uninvolved gland does not improve survival.
Locally Advanced Disease and IVC Thrombus
RCC is the commonest cause of a secondary IVC tumour thrombus in adults; ~90% are clear cell, with ~15% nodal and ~20–25% metastatic disease. Distinguishing tumour thrombus from bland thrombus is critical for operative planning. Suspect a thrombus with lower-limb oedema, a non-collapsing or right-sided varicocele, dilated abdominal-wall veins, proteinuria, PE, a right-atrial mass, or a non-functioning kidney; MRI (or CT) defines the cranial extent and should be imaged close to surgery.
| Level | Cranial extent |
|---|---|
| 0 | Confined to the renal vein |
| I | Within 2 cm of the renal-vein ostium |
| II | Subhepatic (below the hepatic veins) |
| III | Intrahepatic (hepatic veins to diaphragm) |
| IV | Suprahepatic (above the diaphragm) |
45–70% are cured by radical nephrectomy with IVC thrombectomy — even level IV thrombi are curable. For cT4 disease, perform en-bloc resection of involved adjacent organs if feasible (debulking is rarely indicated); vaccinate (pneumococcus, H. influenzae B, meningococcus) before a likely splenectomy.
Prognosis
Pathologic stage is the most important factor:
| pT | 5-year OS |
|---|---|
| T1a / T1b | 90–100% / 80–90% |
| T2a / T2b | 65–80% / 50–70% |
| T3a–c | 20–70% (falling with level) |
| T4 | 0–30% |
Nodal or distant metastasis is dismal (median CSS for pN1 ~2.8 years). Other factors: histologic subtype (collecting-duct, medullary, and sarcomatoid/rhabdoid worse; chromophobe and type 1 papillary better), Fuhrman grade, size, necrosis, and microvascular invasion. Prognostic nomograms include SSIGN, UISS, and Karakiewicz.
Adjuvant Therapy
The standard after resection is observation; high-risk features are grade 3–4, >T2b, unfavourable histology, and nodal involvement. KEYNOTE-564 established adjuvant pembrolizumab for high-risk resected clear-cell RCC (disease-free survival +9% at 24 months, overall survival +8% at 48 months). Adjuvant TKIs are mostly negative — S-TRAC (sunitinib) improved disease-free but not overall survival (FDA-approved), while ASSURE and PROTECT were negative. Neoadjuvant therapy has no role outside a trial.
Surveillance
Renal function dips post-operatively and reaches a new baseline by 3–6 months (monitor creatinine, eGFR, and proteinuria; refer to nephrology if eGFR <45 or CKD progresses). The commonest first-recurrence sites are lung (54%), lymph nodes (22%), bone (20%), and liver (15%). Surveillance intensity follows risk:
| AUA risk group | Definition |
|---|---|
| Low | pT1, grade 1–2 |
| Intermediate | pT1 grade 3–4, or pT2 any grade |
| High | pT3 any grade |
| Very high | pT4, pN1, sarcomatoid/rhabdoid, or positive margin |
Image the abdomen and chest for at least 5 years, more frequently for higher risk (CT chest for high/very-high risk, CXR otherwise). Post-ablation follow-up uses contrast-enhanced CT/MRI, not ultrasound. Isolated local recurrence after RN/PN (2–4%, poor prognosis) can be cured in 30–40% with surgery or ablation.
Self-Test
1. What are the treatment options for localized kidney cancer? Active surveillance, thermal ablation, partial nephrectomy, and radical nephrectomy.
2. Which patients should preferentially have partial over radical nephrectomy? Any feasible cT1a, plus solitary kidney, bilateral or multifocal tumours, familial RCC syndrome, pre-existing CKD or proteinuria, and young patients.
3. When is nephrology referral considered before RCC surgery? eGFR <45, confirmed proteinuria, diabetes with pre-existing CKD, or an expected post-operative eGFR <30.
4. What clinical findings suggest IVC involvement? Lower-limb oedema, a non-reducing or right-sided varicocele, dilated abdominal-wall veins, proteinuria, pulmonary embolism, a right-atrial mass, and a non-functioning kidney.
5. Which adjuvant therapy improves outcomes in high-risk resected clear-cell RCC? Pembrolizumab (KEYNOTE-564) — improved disease-free and overall survival.